AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17664469 — intervention group
Group type: EXPERIMENTAL
Intervention: TCF (TC plus FU 300 mg/m(2)/d on days 1 to 14)
Number of subjects: 119
Study 17664469 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study 16129973 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 12%
Number of subjects: 60
Study 16129973 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane at 3.6%
Number of subjects: 60
Study 12072899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg)
Number of subjects: 12
Study 12072899 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (n=5)
Number of subjects: 12
Study 10091854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadmium-exposed workers
Number of subjects: 32
Study 10091854 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 10091854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadmium body burden (urinary Cd)
Number of subjects: 32
Study 10091854 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead levels
Number of subjects: 32
Study 7587255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing index (1.05) with increased number of nurses
Number of subjects: 87
Study 7587255 — intervention group
Group type: COMPARATOR
Intervention: Nursing index (less than 1.0) with diminished available workforce
Number of subjects: 87
Study 7587255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing index compared with complications and duration of weaning
Number of subjects: 87
Study 2246915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (40 mg every 8 hours)
Number of subjects: 429
Study 2246915 — intervention group
Group type: COMPARATOR
Intervention: Low-dose propranolol (10 mg every 6 hours)
Number of subjects: 429
Study 2246915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sotalol (80 mg every 8 hours)
Number of subjects: 429
Study 2246915 — intervention group
Group type: COMPARATOR
Intervention: High-dose propranolol (20 mg every 6 hours)
Number of subjects: 429
Study 2246915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sotalol
Number of subjects: 429
Study 2246915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sotalol
Number of subjects: 429
Study 2246915 — intervention group
Group type: COMPARATOR
Intervention: Low-dose propranolol
Number of subjects: 429
Study 2246915 — intervention group
Group type: COMPARATOR
Intervention: High-dose propranolol
Number of subjects: 429
Study 6818684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose milk (85% of the lactose hydrolyzed)
Number of subjects: 11
Study 6818684 — intervention group
Group type: COMPARATOR
Intervention: Ordinary cow milk (lactose content, 25 g)
Number of subjects: 11
Study 30816670 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM + MVC group (n=30)
Number of subjects: 60
Study 30816670 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM group (n=30)
Number of subjects: 60
Study 30816670 — intervention group
Group type: COMPARATOR
Intervention: NC group (n=30)
Number of subjects: 60
Study 30816670 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of APN with clinical parameters
Number of subjects: 60
Study 30816670 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AdipoR1 with clinical parameters
Number of subjects: 60
Study 29092881 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) supplements, 40 mEq/d for 3 months
Number of subjects: 29
Study 29092881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25425297 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300 (0.4, 0.6, and 0.9 U/kg)
Number of subjects: 42
Study 25425297 — intervention group
Group type: COMPARATOR
Intervention: Gla-100 (0.4 U/kg)
Number of subjects: 42
Study 24922046 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of rosuvastatin for 6 weeks before carotid artery stenting (CAS)
Number of subjects: 130
Study 24922046 — intervention group
Group type: COMPARATOR
Intervention: Direct carotid stenting without rosuvastatin pretreatment
Number of subjects: 130
Study 18258584 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care and rinses
Number of subjects: 0
Study 18258584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic interventions
Number of subjects: 0
Study 18258584 — intervention group
Group type: EXPERIMENTAL
Intervention: Other techniques
Number of subjects: 0
Study 14732417 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF)
Number of subjects: 92
Study 14732417 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal strivings assessment (PSA)
Number of subjects: 92
Study 14732417 — intervention group
Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 92
Study 11205467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem-cell transplantation (ASCT)
Number of subjects: 372
Study 11205467 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 372
Study 11205467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with ASCT (in patients < 65 years)
Number of subjects: 372
Study 11205467 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (in patients < 65 years)
Number of subjects: 372
Study 9084194 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical doxymycine
Number of subjects: 31
Study 9084194 — intervention group
Group type: COMPARATOR
Intervention: Calcii gluconase (Control)
Number of subjects: 31
Study 8366182 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 300 mg chewable tablet after overnight fast
Number of subjects: 10
Study 8366182 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 300 mg chewable tablet 30 minutes before a meal
Number of subjects: 10
Study 8366182 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 300 mg chewable tablet 1 hour before a meal
Number of subjects: 10
Study 8366182 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 300 mg chewable tablet 1 hour after a meal
Number of subjects: 10
Study 8366182 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 300 mg chewable tablet 2 hours after a meal
Number of subjects: 10
Study 3519020 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 20
Study 3519020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30647044 — intervention group
Group type: EXPERIMENTAL
Intervention: BDD-NET (therapist-guided internet-based cognitive behavioural therapy)
Number of subjects: 88
Study 28306389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (200 mg, 300 mg, 500 mg single dose)
Number of subjects: 501
Study 28306389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (100 mg, 200 mg, 300 mg two doses at days 1 and 90)
Number of subjects: 501
Study 28306389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (300 mg two doses)
Number of subjects: 501
Study 28306389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 28306389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 501
Study 25326088 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines on treatment of RTIs and uncomplicated lower UTIs with sustained, regular feedback on individual antibiotic prescription behaviour during 2 years
Number of subjects: 140
Study 25326088 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 140
Study 25028096 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental carbon ultrafine particles (107 particles/cm3, 50 ug/m3, count median diameter 32 nm)
Number of subjects: 17
Study 25028096 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (0-10 particles/cm3)
Number of subjects: 17
Study 22965965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg plus FOLFOX/CAPOX
Number of subjects: 860
Study 22965965 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFOX/CAPOX
Number of subjects: 860
Study 19006537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 mcg twice daily
Number of subjects: 1171
Study 19006537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1171
Study 17357862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant application before drain insertion
Number of subjects: 32
Study 17357862 — intervention group
Group type: COMPARATOR
Intervention: Standard Limberg flap technique
Number of subjects: 32
Study 15194675 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 8
Study 15194675 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 11489038 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research
Number of subjects: 0
Study 8996340 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week prophylactic course of bacillus Calmette-Guerin (BCG)
Number of subjects: 70
Study 8996340 — intervention group
Group type: COMPARATOR
Intervention: 6-week course of bacillus Calmette-Guerin (BCG)
Number of subjects: 70
Study 8483096 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue autografts (CTGs)
Number of subjects: 10
Study 8483096 — intervention group
Group type: COMPARATOR
Intervention: Thick free gingival autografts (FGGs)
Number of subjects: 10
Study 2825469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 11
Study 2825469 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 11
Study 2825469 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol control
Number of subjects: 11
Study 2825469 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (6 mg/kg)
Number of subjects: 11
Study 2825469 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 11
Study 31707069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient + partner intervention
Number of subjects: 301
Study 31707069 — intervention group
Group type: COMPARATOR
Intervention: Patient-only intervention
Number of subjects: 301
Study 29292242 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor 90 mg twice daily
Number of subjects: 22
Study 29292242 — intervention group
Group type: COMPARATOR
Intervention: prasugrel 10 mg once daily
Number of subjects: 22
Study 26460569 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 538
Study 26460569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine craving increases
Number of subjects: 538
Study 23963690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) soybean, olive oil, and fish oil emulsion
Number of subjects: 130
Study 23963690 — intervention group
Group type: COMPARATOR
Intervention: Parenteral soybean and olive oil emulsion (control)
Number of subjects: 130
Study 22390886 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered physical activity and healthy nutrition program with monthly email messages and additional web-based tools.
Number of subjects: 924
Study 22390886 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly email messages to promote website visits during the first year.
Number of subjects: 924
Study 22390886 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 924
Study 20869041 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week treatment for BED
Number of subjects: 179
Study 19012472 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 40
Study 19012472 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal individuals)
Number of subjects: 40
Study 16027343 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected hyaluronidase
Number of subjects: 0
Study 16027343 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 16027343 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected hyaluronidase (3 different doses)
Number of subjects: 0
Study 14709299 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% eyedrops
Number of subjects: 136
Study 14709299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1% eyedrops
Number of subjects: 136
Study 14709299 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% eyedrops (placebo)
Number of subjects: 136
Study 10633491 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid (AA) mixture (n = 14)
Number of subjects: 41
Study 10633491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan deficient mixture (n = 15)
Number of subjects: 41
Study 10633491 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine/tyrosine deficient mixture (n = 12)
Number of subjects: 41
Study 9102029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 20
Study 9102029 — intervention group
Group type: COMPARATOR
Intervention: Radiographs
Number of subjects: 20
Study 1281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal alpha-amylase and cellulase
Number of subjects: 5
Study 1281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial challenge tests with alpha-amylase and cellulase
Number of subjects: 5
Study 1281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot analysis with pooled serum
Number of subjects: 5
Study 1281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse-enzyme immunoassay-inhibition assays
Number of subjects: 5
Study 1281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Aspergillus-derived enzymes as flour additives
Number of subjects: 5
Study 6608052 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (coronary bypass surgery)
Number of subjects: 780
Study 6608052 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study 30516416 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text message reminders (N = 42)
Number of subjects: 79
Study 30516416 — intervention group
Group type: COMPARATOR
Intervention: Weekly text message reminders (N = 37)
Number of subjects: 79
Study 29757823 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT) - ISWT-1
Number of subjects: 27
Study 29757823 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT) - ISWT-2
Number of subjects: 27
Study 29757823 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT) - ISWT-1 vs ISWT-3 after pulmonary rehabilitation (PR)
Number of subjects: 27
Study 27040362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 164
Study 27040362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 164
Study 27040362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low non-HDL-C level (≤140 mg/dl)
Number of subjects: 164
Study 27040362 — intervention group
Group type: COMPARATOR
Intervention: Low cholesterol group (≤140 mg/dl)
Number of subjects: 164
Study 25130584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (phosphodiesterase enzyme-5 inhibitor)
Number of subjects: 0
Study 25130584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23307089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromure and probiotics for 3 weeks
Number of subjects: 51
Study 23307089 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromure and placebo for 3 weeks
Number of subjects: 51
Study 20077495 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+ERL (scaling and root planing followed by fluorescence controlled Er:YAG laser)
Number of subjects: 30
Study 20077495 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 30
Study 17611706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild vertebral fractures
Number of subjects: 3358
Study 17611706 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one grade >= 2 vertebral fracture at baseline
Number of subjects: 3358
Study 17611706 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident mild fractures only during the first 2 years
Number of subjects: 3358
Study 17611706 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one grade >= 2 incident fracture during the first 2 years
Number of subjects: 3358
Study 17611706 — intervention group
Group type: EXPERIMENTAL
Intervention: Only mild vertebral fractures at baseline
Number of subjects: 3358
Study 17611706 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged more than 70 years with only mild vertebral fractures
Number of subjects: 3358
Study 17611706 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged more than 70 years with at least one grade >= 2 vertebral fracture
Number of subjects: 3358
Study 15860392 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day for 3 days
Number of subjects: 27
Study 15860392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11939924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/mL with sufentanil 0.75 microg/mL
Number of subjects: 114
Study 11939924 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 1.25 mg/mL with sufentanil 0.75 microg/mL
Number of subjects: 114
Study 9830244 — intervention group
Group type: EXPERIMENTAL
Intervention: HIA-CP boys
Number of subjects: 0
Study 9830244 — intervention group
Group type: COMPARATOR
Intervention: HIA-only boys
Number of subjects: 0
Study 9830244 — intervention group
Group type: COMPARATOR
Intervention: non-HIA-CP boys
Number of subjects: 0
Study 9830244 — intervention group
Group type: COMPARATOR
Intervention: CP only boys
Number of subjects: 0
Study 7851363 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated with water ad libitum
Number of subjects: 10
Study 7851363 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated with no water intake (NW)
Number of subjects: 10
Study 7851363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated (HY, -3.8 (SD 0.7)% body mass) with water ad libitum
Number of subjects: 10
Study 7851363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated (HY, -3.8 (SD 0.7)% body mass) with no water intake (NW)
Number of subjects: 10
Study 2572140 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine nocte
Number of subjects: 30
Study 2572140 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine given morning and evening
Number of subjects: 30
Study 2572140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1096829 — intervention group
Group type: EXPERIMENTAL
Intervention: Agar (600 mg/kg daily for 7 days, starting at 12 hours of age)
Number of subjects: 80
Study 1096829 — intervention group
Group type: EXPERIMENTAL
Intervention: Agar (700 mg/kg daily for 7 days, starting at 6 hours of age)
Number of subjects: 80
Study 1096829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no agar)
Number of subjects: 80
Study 31812328 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype GG of rs7936070
Number of subjects: 1556
Study 31812328 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype AA of rs7927894
Number of subjects: 1556
Study 31812328 — intervention group
Group type: COMPARATOR
Intervention: C11orf30 expression in serum
Number of subjects: 1556
Study 31034728 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education on perioperative crises (Laryngospasm, Bronchospasm, Supraventricular Tachycardia (SVT), and Bradycardia) during the first week of an eight-week rotation (Group A)
Number of subjects: 30
Study 31034728 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education on perioperative crises during the fifth week of an eight-week rotation (Group B)
Number of subjects: 30
Study 28851329 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional daily school-time physical activity (PA)
Number of subjects: 24
Study 28851329 — intervention group
Group type: EXPERIMENTAL
Intervention: Villa Vitality (VV), a 6-week healthy lifestyle promotion programme
Number of subjects: 24
Study 28851329 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention implementation
Number of subjects: 24
Study 28851329 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher logbooks vs researcher observations
Number of subjects: 24
Study 25344064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dantrolene (IV‐D) 1.25 mg every 6 hours for 7 days (n=16)
Number of subjects: 31
Study 25344064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equisosmolar free water/5% mannitol; n=15)
Number of subjects: 31
Study 23842710 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan
Number of subjects: 20
Study 23842710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21950041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidrum (ED)
Number of subjects: 40
Study 21950041 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance (LOR)
Number of subjects: 40
Study 20110024 — intervention group
Group type: EXPERIMENTAL
Intervention: Etizolam 0.5 mg BID
Number of subjects: 77
Study 20110024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 17007849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole for 5 days (cycle days 3‐7) followed by FSH injections (days 7‐11)
Number of subjects: 50
Study 17007849 — intervention group
Group type: COMPARATOR
Intervention: 100 mg clomiphene citrate for 5 days (cycle days 3‐7) followed by FSH injections (days 7‐11)
Number of subjects: 50
Study 17007849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole
Number of subjects: 50
Study 17007849 — intervention group
Group type: COMPARATOR
Intervention: 100 mg clomiphene citrate
Number of subjects: 50
Study 17007849 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate cycles
Number of subjects: 50
Study 15503077 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily energy expenditure (TEE)
Number of subjects: 36
Study 15503077 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting metabolic rate (RMR)
Number of subjects: 36
Study 15503077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake
Number of subjects: 36
Study 15503077 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and body composition measurements
Number of subjects: 36